Translational research in women's health: From bedside to bench and from bench to bedside

Maruo, Takeshi

doi:10.1016/j.ijgo.2010.01.003

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRI examination, however, revealed that myoma volume during use of the device decreased in some instances, but increased in the other instances [12,13]. This unexpected finding with MRI led us to characterize the effects of progesterone (P4) on uterine leiomyoma cell growth in vitro.…”

Section: Introductionmentioning

confidence: 99%

Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas

Maruo

Ohara

Yoshida

et al. 2011

Expert Opinion on Drug Discovery

Self Cite

View full text Add to dashboard Cite

In consistence with the in vitro data obtained, randomized controlled clinical trials of PRMs in patients with uterine leiomyomas at several institutions have demonstrated that oral administration of PRMs (asoprisnil and ulipristal) for 3 months reduced leiomyoma volume, resulting in a significant improvement of the associated symptoms. However, a novel pattern of PRM-associated endometrial changes was recognized in the endometrial pathology, demonstrating unusual epithelial types not seen in the normal menstrual cycle of a premenstrual woman. Thus, follow-up studies to determine whether the novel endometrial changes remain, disappear or progress to something else are needed for the possible long-term use of PRMs for the treatment of uterine leiomyoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas

Maruo

Ohara

Yoshida

et al. 2011

Expert Opinion on Drug Discovery

Self Cite

View full text Add to dashboard Cite

show abstract

Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids

Talaulikar

Manyonda

2012

Adv Therapy

View full text Add to dashboard Cite

Fibroids, the most common tumor in women of reproductive age, impact negatively on women's health and quality of life, and have significant cost implications for their management. The current mainstay treatments are surgical (myomectomy and hysterectomy) and more recently radiological (UAE and focused ultrasound surgery). Hysterectomy is curative but precludes future fertility, whereas the impact of the other treatments on reproduction is uncertain. With women in Western societies deferring childbearing to their 30s and 40s, when fibroids are most symptomatic, there is a pressing need for a uterus-sparing medical therapy that is cheap, effective, and enhances reproductive potential. Serendipity and meticulous translational research has shown that progesterone augments fibroid proliferation, raising the possibility that progesterone receptor modulators could inhibit fibroid growth; this research has culminated in the emergence of ulipristal acetate (UA), a first-in-class, oral selective progesterone receptor modulator (SPRM) that has successfully completed phase III clinical trials. It has been licensed in Western Europe for short-term clinical use prior to surgery, and has shown efficacy with a significant reduction in uterine bleeding, fibroid volume, and improved quality of life, without the side effects associated with other medications such as gonadotropin-releasing hormone (GnRH) agonists. As with all new medicines, there are concerns surrounding UA, not least its effect on the endometrium and the long-term impact on general health and reproduction. Research to date has tended to be industry led, and therefore, there is a need for researcher/clinician-led studies to address the wider issues concerning SPRMs. UA may not turn out to be the "Holy Grail" of medical therapy in the treatment of symptomatic uterine fibroids, but it has rightly given cause for a huge optimism. Further laboratory and clinical research into PRMs and related compounds will no doubt lead to more refined medications.

show abstract

Innovative approaches in the treatment of the uterine myoma to restore reproductive function

Fedorovich

Vladimirovich

Gennadievna

et al. 2015

Gynecological Endocrinology

View full text Add to dashboard Cite

Translational research in women's health: From bedside to bench and from bench to bedside

Cited by 3 publications

References 21 publications

Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas

Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas

Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids

Innovative approaches in the treatment of the uterine myoma to restore reproductive function

Contact Info

Product

Resources

About